Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma August 24, 2020 Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... February 23, 2023 Load more HOT NEWS Can Topical Drugs Help Prevent Breast Cancer? Woman, 88, Had Been Waving from Her Window for Over a... New on NCI’s Websites, March 2020 For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily
